Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate

Benzinga15:05 ET

Novo Nordisk to Further Scale Up Production, Supply, Employment -- Market Talk

WSJJan 22 05:24 ET

This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com

Barron's07:38 ET

Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.

Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.

wallstreetcn06:52 ET

Novo Nordisk Very Interested in Small Nuclear Reactors, Chairman Says -- Market Talk

WSJ06:26 ET

IMMvention Therapeutix Enters Collaboration With Novo Nordisk for Sickle Cell Disease Therapies

Seeking AlphaJan 22 08:59 ET